SpyGlass Pharma, Inc. SGP 深 滬
等待開盤 03-26 09:30:00 美东时间
25.22
+1.480
+6.23%
華盛通- 最 高25.96
- 今 開23.64
- 成交量 7.26万股
- 最 低 23.64
- 昨 收 23.74
- 總市值 8.40亿
- 52周最高 32.44
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 20.16
- 委 比 99.60%
- 總股本 3331.74万
- 歷史最高 32.44
- 量 比 0.26
- 振 幅 9.77%
- 歷史最低 20.16
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
HC Wainwright & Co. Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $37
HC Wainwright & Co. analyst Yi Chen initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $37.
03-10 19:14
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Stifel Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42
Stifel analyst Tom Stephan initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $42.
03-03 18:41
UPDATE 2-Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO
UPDATE 2-Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO Adds background and details in paragraphs 4-7 Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion its initial public offering in the United Stat
02-23 19:54
